These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 18312210)

  • 1. Accommodating uncertainty in a tree set for function estimation.
    Healy BC; DeGruttola VG; Hu C
    Stat Appl Genet Mol Biol; 2008; 7(1):Article5. PubMed ID: 18312210
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nucleoside reverse transcriptase inhibitor resistance mutations in subtype F1 strains isolated from heavily treated adolescents in Romania.
    Paraschiv S; Otelea D; Baicus C; Tinischi M; Costache M; Neaga E
    Int J Infect Dis; 2009 Jan; 13(1):81-9. PubMed ID: 18632295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral combinations implicated in emergence of the L74I and L74V resistance mutations in HIV-1-infected patients.
    Wirden M; Lambert-Niclot S; Marcelin AG; Schneider L; Ait-Mohand H; Brunet C; Angleraud F; Amard S; Katlama C; Calvez V
    AIDS; 2009 Jan; 23(1):95-9. PubMed ID: 19050391
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evidence of dual sexual transmission of multi-resistant HIV with two years persistence of resistance to NRTI and NNRTI: a case report.
    Zaccarelli M; Marconi P; Visco-Comandini U; Liuzzi G; Sette P; Acinapura R; Mosti S; Ammassari A; Perno CF; Antinori A
    Infection; 2008 Mar; 36(2):178-80. PubMed ID: 17962906
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 resistance to first- and second-generation non-nucleoside reverse transcriptase inhibitors.
    Ghosn J; Chaix ML; Delaugerre C
    AIDS Rev; 2009; 11(3):165-73. PubMed ID: 19654858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Research on the selective kinetics of HIV-1 nucleoside reverse transcriptase inhibitor drug resistance-associated mutations among 4 AIDS patients receiving highly active antiretroviral therapy].
    Li J; Jiao LY; Li HP; Li L; Liu YJ; Zhuang DM; Liu SY; Bao ZY; Li H; Wang Z; Li JY
    Zhonghua Liu Xing Bing Xue Za Zhi; 2008 Aug; 29(8):794-800. PubMed ID: 19103117
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model selection for mixtures of mutagenetic trees.
    Yin J; Beerenwinkel N; Rahnenführer J; Lengauer T
    Stat Appl Genet Mol Biol; 2006; 5():Article17. PubMed ID: 17049028
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary drug resistance in antiretroviral-naïve injection drug users.
    Tossonian HK; Raffa JD; Grebely J; Viljoen M; Mead A; Khara M; McLean M; Krishnamurthy A; DeVlaming S; Conway B
    Int J Infect Dis; 2009 Sep; 13(5):577-83. PubMed ID: 19111493
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Resistance to nucleoside reverse transcriptase inhibitors].
    Leal M; Santamaría JM
    Enferm Infecc Microbiol Clin; 2001 Feb; 19(Monografico):26-9. PubMed ID: 11428055
    [No Abstract]   [Full Text] [Related]  

  • 10. Compilation and prevalence of mutations associated with resistance to non-nucleoside reverse transcriptase inhibitors.
    Tambuyzer L; Azijn H; Rimsky LT; Vingerhoets J; Lecocq P; Kraus G; Picchio G; de Béthune MP
    Antivir Ther; 2009; 14(1):103-9. PubMed ID: 19320243
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug resistant mutations detected by genotypic drug resistance testing in patients failing therapy in clade C HIV-1 infected individuals from India.
    Kandathil AJ; Kannangai R; Verghese VP; Pulimood SA; Rupali P; Sridharan G; Grant P; Pillay D; Abraham OC
    Indian J Med Microbiol; 2009; 27(3):231-6. PubMed ID: 19584504
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidden Markov models for settings with interval-censored transition times and uncertain time origin: application to HIV genetic analyses.
    Healy B; Degruttola V
    Biostatistics; 2007 Apr; 8(2):438-52. PubMed ID: 16940036
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Profile of drug resistance mutations among HIV-1-infected Tunisian subjects failing antiretroviral therapy.
    Jlizi A; Ben Ammar El Gaaied A; Slim A; Tebourski F; Ben Mamou M; Ben Chaabane T; Letaief-Omezzine A; Chakroun M; Garbouj M; Ben Rejeb S
    Arch Virol; 2008; 153(6):1103-8. PubMed ID: 18483694
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-nucleoside HIV-1 reverse transcriptase inhibitors di-halo-indolyl aryl sulfones achieve tight binding to drug-resistant mutants by targeting the enzyme-substrate complex.
    Samuele A; Kataropoulou A; Viola M; Zanoli S; La Regina G; Piscitelli F; Silvestri R; Maga G
    Antiviral Res; 2009 Jan; 81(1):47-55. PubMed ID: 18984007
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Non-parametric methods to predict HIV drug susceptibility phenotype from genotype.
    DiRienzo AG; DeGruttola V; Larder B; Hertogs K
    Stat Med; 2003 Sep; 22(17):2785-98. PubMed ID: 12939786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prevalence of the K65R resistance reverse transcriptase mutation in different HIV-1 subtypes in Israel.
    Turner D; Shahar E; Katchman E; Kedem E; Matus N; Katzir M; Hassoun G; Pollack S; Kessner R; Wainberg MA; Avidor B
    J Med Virol; 2009 Sep; 81(9):1509-12. PubMed ID: 19626612
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nucleoside reverse transcriptase inhibitor-sparing regimen (nonnucleoside reverse transcriptase inhibitor + protease inhibitor) was more likely associated with resistance comparing to nonnucleoside reverse transcriptase inhibitor or protease inhibitor + nucleoside reverse transcriptase inhibitor in the randomized ANRS 121 trial.
    Soulié C; Assoumou L; Ghosn J; Duvivier C; Peytavin G; Ait-Arkoub Z; Molina JM; Costagliola D; Katlama C; Calvez V; Marcelin AG
    AIDS; 2009 Jul; 23(12):1605-8. PubMed ID: 19487903
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HIV-1-resistant strains during 8-week on 8-week off intermittent therapy and their effect on CD4+ T-cell counts and antiviral response.
    Izopet J; Marchou B; Charreau I; Sauné K; Tangre P; Molina JM; Aboulker JP;
    Antivir Ther; 2008; 13(4):537-45. PubMed ID: 18672532
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence, genotypic associations and phenotypic characterization of K65R, L74V and other HIV-1 RT resistance mutations in a commercial database.
    McColl DJ; Chappey C; Parkin NT; Miller MD
    Antivir Ther; 2008; 13(2):189-97. PubMed ID: 18505170
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.